PMDA drug package insert
アバスチン点滴静注用100mg/4mL
PMDA Prescription drug · 中外製薬株式会社 · package insert Jun 19, 2026
Key facts
| Brand names | アバスチン点滴静注用100mg/4mL, アバスチン点滴静注用400mg/16mL |
|---|---|
| Nonproprietary names | ベバシズマブ（遺伝子組換え） |
| Companies | 製造販売元／中外製薬株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 抗悪性腫瘍剤; 抗VEGFヒト化モノクローナル抗体VEGF：Vascular Endothelial Growth Factor（血管内皮増殖因子） |
| Therapeutic category codes | 874291 |
| YJ codes | 4291413A1022, 4291413A2029 |
| Approval numbers | 21900AMX00910, 21900AMX00921 |
| Package insert edition | 第7版 |
| Package insert date | Jun 19, 2026 |
| PMDA document key | 450045_4291413A1022_1 |
| PMDA company code | 450045 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- 1–9 Safety communications
- Yes PMDA review report published
- Yes Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: